Collaboration Agreements - Additional Information (Details) - USD ($)	1 Months Ended	3 Months Ended						9 Months Ended		12 Months Ended	66 Months Ended
	Apr. 30, 2015	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2019	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2016	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2017	Sep. 30, 2020
Novartis Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement	$ 200,000,000.0						$ 35,000,000.0				$ 2,100,000
Novartis share of joint development costs								38.00%
Period after first commercial sale of product on which Novartis' royalty obligation run on a country to country basis								12 years
Remaining performance obligations		$ 237,100,000						$ 237,100,000			237,100,000
Revenue recognized		1,600,000		$ 2,400,000				7,200,000	$ 6,800,000
Deferred revenue		161,800,000						$ 161,800,000			161,800,000
Novartis Agreement | United States
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement profit share percentage								50.00%
Novartis Agreement | European Countries and Japan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative arrangement profit share percentage								45.00%
Novartis Agreement | United States, Specified European Countries and /or Japan
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Agreement, Obligations								With respect to the United States, specified European countries and/or Japan, Aduro may elect for such region to either reduce by 50% or to eliminate in full Aduro’s development and commercialization cost sharing obligation. If Aduro elects to reduce its cost sharing percentage by 50% in any such region, then its profit share in such region will also be reduced by 50%. If Aduro elects to eliminate its development cost sharing obligation, then such region will be removed from the profit share, and instead Novartis will owe Aduro royalties on any net sales of product for such region, as described above.
Reduction percentage of development cost share								50.00%
Reduction percentage of profit share								50.00%
Novartis Agreement | Novartis
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Novartis share of joint development costs								62.00%
Collaborative arrangement profit share percentage								50.00%
Novartis Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestones amount eligible to receive								$ 215,000,000.0
Regulatory approval milestones amount eligible to receive								250,000,000.0
Lilly Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement					$ 12,000,000.0			12,000,000.0
Revenue recognized		2,200,000		$ 2,400,000				6,100,000	$ 6,800,000
Deferred revenue		1,800,000						$ 1,800,000			1,800,000
Royalty payments receivable terms								Lilly is also obligated to pay Aduro tiered royalty payments at percentages in the single to low-double digits based on annual net sales of the licensed products. Lilly must pay such royalties on a product-by-product and country-by-country basis until the latest to occur of (i) the expiration of the last-to-expire valid claim of certain patents, (ii) the expiration of the data exclusivity period in such country or (iii) a specified anniversary of the first commercial sale of such product in such country.
Lilly Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates								$ 620,000,000.0
Merck License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Payments received under collaboration agreement			$ 10,000,000.0			$ 3,000,000.0				$ 2,000,000.0
Remaining performance obligations		0				$ 0		0		$ 0	$ 0
Revenue recognized		$ 0
Milestone payment								10,000,000.0
Merck License Agreement | Maximum | Product Candidate
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates								297,000,000.0
Merck License Agreement | Maximum | Product
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone amount eligible to receive for products or product candidates								$ 135,000,000.0